Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Patterson

Showing results (71-80 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|August 5, 2008
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infectionGeorge R Thompson, Nathan P Wiederhold, Ana C Vallor, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformansGeorge R Thompson, Nathan P Wiederhold, Annette W Fothergill, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal MeningitisNathan P Wiederhold, Laura Kovanda, Laura K Najvar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2021
Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal DiseaseP Lewis White, Stephane Bretagne, Angela M Caliendo, et al.
Pharmacotherapy|June 2, 2005
Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosisJames S Lewis, Helen W Boucher, Teresa J Lubowski, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2008
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformansGeorge R Thompson, Annette W Fothergill, Nathan P Wiederhold, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2019
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatusNathan P Wiederhold, Laura K Najvar, Rosie Jaramillo, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2016
Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal TractDavid Kadosh, Laura K Najvar, Rosie Bocanegra, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2021
Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant Candida auris and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive CandidiasisNathan P Wiederhold, Laura K Najvar, Marcos Olivo, et al.
Revista Iberoamericana De Micologia|June 28, 2003
Proteinase detection, DNA typing and antimycotic susceptibility of Candida isolates from Colombian women with vulvovaginal candidiasisNora Cardona-Castro, Sanjay G Revankar, Patricia Ortiz, et al.
Pageof 21

Showing results (71-80 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|August 5, 2008
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infectionGeorge R Thompson, Nathan P Wiederhold, Ana C Vallor, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformansGeorge R Thompson, Nathan P Wiederhold, Annette W Fothergill, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal MeningitisNathan P Wiederhold, Laura Kovanda, Laura K Najvar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2021
Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal DiseaseP Lewis White, Stephane Bretagne, Angela M Caliendo, et al.
Pharmacotherapy|June 2, 2005
Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosisJames S Lewis, Helen W Boucher, Teresa J Lubowski, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2008
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformansGeorge R Thompson, Annette W Fothergill, Nathan P Wiederhold, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2019
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatusNathan P Wiederhold, Laura K Najvar, Rosie Jaramillo, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2016
Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal TractDavid Kadosh, Laura K Najvar, Rosie Bocanegra, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2021
Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant Candida auris and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive CandidiasisNathan P Wiederhold, Laura K Najvar, Marcos Olivo, et al.
Revista Iberoamericana De Micologia|June 28, 2003
Proteinase detection, DNA typing and antimycotic susceptibility of Candida isolates from Colombian women with vulvovaginal candidiasisNora Cardona-Castro, Sanjay G Revankar, Patricia Ortiz, et al.
Pageof 21